Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience

Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience

Importance: Deregulation of anaplastic lymphoma kinase (ALK) occurs in 3–7% of advanced NSCLC mainly because of chromosomic rearrangements at the ALK locus. Next to its oncogenic function, ALK chimeric oncoprotein is a possible antigen for human immune system. The prognostic value of natural anti-AL...

Full description

Saved in:

Bibliographic Details
Main Authors:	Claudia Parisi, José Carlos Benitez, Hélène Lecourt, Filippo Gustavo dall’Olio, Mihaela Aldea, Felix Blanc-Durand, Véronique Vergé, Cyril Quivoron, Charles Naltet, Pamela Abdayem, Pernelle Lavaud, Maria Rosa Ghigna, Luc Friboulet, Yohann Loriot, Stéphane De Botton, Vincent Ribrag, Andrea Ardizzoni, David Planchard, Jean-Charles Soria, Fabrice Barlesi, Benjamin Besse
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	The Journal of Liquid Biopsy
Subjects:	Anaplastic lymphoma kinase ALK Lung cancer NSCLC Circulating antibodies Immunogenicity
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950195424000298
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

MBNL2-ALK: A novel ALK fusion transcript in a sinonasal melanoma
by: Elena Bolzacchini, et al.
Published: (2024-12-01)

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
by: Seema Chugh, et al.
Published: (2025-02-01)

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01)

First-Line Treatment of _ALK_-Positive NSCLC
by: Hasna Bouchaab
Published: (2020-11-01)

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
by: Federica Malighetti, et al.
Published: (2024-12-01)

Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
by: Mingyue Wang, et al.
Published: (2025-02-01)

Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer
by: Zihua Zou, et al.
Published: (2025-01-01)

ACTIVE-LEARNING METHOD BASED ON ALK MODEL AND SUBSET SIMULATION
by: LIU ZeQing, et al.
Published: (2024-02-01)

A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01)

The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors.
by: Eun-Jeong Yu, et al.
Published: (2024-01-01)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
by: T. Lee Collier PhD, et al.
Published: (2017-10-01)

Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany
by: Nikolaj Rischke, et al.
Published: (2024-12-01)

A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review
by: Shuzhe Yang, et al.
Published: (2025-01-01)

Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer
by: Francois-Xavier Danlos, et al.
Published: (2024-11-01)

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer
by: Koh Furugaki, et al.
Published: (2025-02-01)

An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor
by: Sanjivini V. Jacob, et al.
Published: (2014-01-01)

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01)

ALK + anaplastic large cell lymphoma involving the bladder: case report and review of the literature
by: Ying Zhao, et al.
Published: (2024-12-01)

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome
by: Mingyuan Du, et al.
Published: (2024-12-01)

Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
by: Weizhen SUN, et al.
Published: (2024-11-01)

Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
by: Qian Huang, et al.
Published: (2022-09-01)

T<scp>ree</scp>T<scp>alk</scp>: Composition and Compression of Trees for Image Descriptions
by: Polina Kuznetsova, et al.
Published: (2021-03-01)

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
by: Kyuhwan Kim, et al.
Published: (2025-02-01)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
by: Luca Mastrantoni, et al.
Published: (2024-01-01)

Corrigendum: Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
by: Qian Huang, et al.
Published: (2024-12-01)

Recurrent Inflammatory Myofibroblastic Tumor of Larynx Harboring a Novel THBS1::ALK Fusion
by: Namra Ajmal, et al.
Published: (2024-01-01)

Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma
by: Laura S. Lourdes, et al.
Published: (2012-01-01)

A Rare Case of ALK-Positive Large B-Cell Lymphoma with CD33 Expression
by: Jessica Corean, et al.
Published: (2018-01-01)

Brain Metastasis Mimicking Brain Abscess in ALK-Positive Non-Small-Cell Lung Cancer
by: Toshio Sakatani, et al.
Published: (2019-01-01)

The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients
by: Li Wang, et al.
Published: (2024-01-01)

PRIMARY PALATAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: RARITY TREATED SUCCESSFULLY WITH BRENTUXIMAB VEDOTIN
by: Müjgan Çözeli, et al.
Published: (2024-12-01)

Synthesis, in silico studies and in vitro cytotoxicity evaluation of novel posaconazole derivative as a ALK TK inhibitor
by: Rahul D. Jawarkar, et al.
Published: (2024-12-01)

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
by: Yang Zhang, et al.
Published: (2025-01-01)

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
by: Sung Sook Lee, et al.
Published: (2020-10-01)

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01)

ALK-Positive Anaplastic Large Cell Lymphoma: A Diagnostic Dilemma for the Otolaryngologist in a Resource Poor Setting
by: Nicholas Figaro, et al.
Published: (2021-01-01)

Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response
by: Thomas Cochin, et al.
Published: (2025-01-01)

Non-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report
by: Mohamad Hadhud, et al.
Published: (2025-01-01)

Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer
by: Magdalena Zaborowska-Szmit, et al.
Published: (2024-11-01)

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
by: Jialin Qian, et al.
Published: (2025-03-01)